Duloxetine
Brand names: Cymbalta
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)Key Takeaway
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
⚠ FDA Black Box Warning
Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. Duloxetine is not approved for use in pediatric patients.
Emergency Information
Poison Control: 1-800-222-1222
How does Duloxetine work?
Duloxetine belongs to the SNRI (serotonin-norepinephrine reuptake inhibitor) class of antidepressants [1, 10]. It works by blocking the reuptake of two key neurotransmitters in the brain: serotonin and norepinephrine. By preventing these neurotransmitters from being reabsorbed back into nerve cells, duloxetine increases their availability in the synaptic cleft — the gap between neurons where chemical signaling occurs [1, 10].
Serotonin plays a central role in regulating mood, anxiety, sleep, and appetite [1]. Low serotonin activity is associated with depression and anxiety disorders. By increasing serotonin signaling, duloxetine helps stabilize mood, reduce anxiety, and improve emotional well-being [3, 6].
Norepinephrine is involved in alertness, energy, attention, and the modulation of pain signals [1]. By boosting norepinephrine levels, duloxetine helps address fatigue and concentration problems that often accompany depression. Critically, norepinephrine also plays a major role in the brain's descending pain inhibitory pathways — neural circuits that travel from the brain down the spinal cord and act to suppress pain signals before they reach conscious awareness [1, 4].
This dual mechanism — acting on both serotonin and norepinephrine — is what makes duloxetine uniquely effective for conditions that involve both mood disturbance and chronic pain [1, 10]. It is why duloxetine is one of the few antidepressants also FDA-approved for pain conditions like diabetic neuropathy, fibromyalgia, and chronic musculoskeletal pain [4, 5, 14].
Duloxetine begins working within the first week in terms of neurochemical changes, but noticeable clinical improvement in depression and anxiety typically takes 2-4 weeks [1, 3]. Pain relief may be noticed somewhat sooner, often within 1-2 weeks [4]. A large network meta-analysis in the Lancet confirmed duloxetine's efficacy relative to other antidepressants for major depression [13].
What to expect when starting Duloxetine
When you start duloxetine, your doctor will typically begin with 30 mg once daily for 1-2 weeks, then increase to the target dose of 60 mg once daily [1]. This gradual start helps minimize initial side effects, particularly nausea.
The most common initial side effects are nausea, dry mouth, constipation, decreased appetite, and fatigue [1, 3]. Nausea is the most frequent early side effect, affecting up to 25% of patients, but it typically improves substantially within the first 1-2 weeks [1, 3].
For depression and anxiety, meaningful improvement usually takes 2-4 weeks of consistent use at an adequate dose [1, 3, 6]. Some patients notice subtle improvements in sleep, appetite, or energy before mood fully improves. Full antidepressant effect may take 6-8 weeks [3].
For pain conditions (diabetic neuropathy, fibromyalgia, chronic musculoskeletal pain), some pain relief may be noticed within the first 1-2 weeks, with maximum benefit typically reached by 4-6 weeks [4, 5, 14].
Duloxetine may cause initial insomnia or drowsiness — the timing of your dose can be adjusted accordingly [1]. If it causes drowsiness, take it in the evening; if it causes insomnia, take it in the morning.
Do not stop duloxetine abruptly [1, 8]. Sudden discontinuation can cause withdrawal symptoms (dizziness, nausea, headache, irritability, electric shock sensations — sometimes called "brain zaps") [8]. Perahia et al. documented that these discontinuation symptoms can occur even after brief courses of treatment [8]. Your doctor will guide a gradual taper if you need to stop.
What are the common side effects of Duloxetine?
Common
- Nausea20-25%
- Dry mouth13-15%
- Headache13-14%
- Fatigue/somnolence8-11%
- Constipation9-11%
- Dizziness9-10%
- Decreased appetite7-8%
- Increased sweating (hyperhidrosis)6-7%
- Insomnia9-11%
- Sexual dysfunction (decreased libido, erectile dysfunction, anorgasmia)3-9%
- Tremor2-3%
- Diarrhea7-9%
What are the serious side effects of Duloxetine?
Serious
- Suicidal thoughts and behavior (in young adults)Increased risk in patients under 25; closely monitor
- Serotonin syndromeRare; risk increases with serotonergic combinations
- HepatotoxicityRare; cases of hepatic failure reported
- Severe skin reactions (Stevens-Johnson syndrome, erythema multiforme)Very rare
- Hyponatremia (SIADH)Uncommon; higher risk in elderly and those on diuretics
- Orthostatic hypotension and syncope1-2%; more common during first week
- Mania/hypomania activation<1%
- Angle-closure glaucomaVery rare
What drugs interact with Duloxetine?
- MajorMAO inhibitors (selegiline, phenelzine, tranylcypromine) — CONTRAINDICATED. Do not use duloxetine within 14 days of stopping an MAOI, and do not start an MAOI within 5 days of stopping duloxetine. The combination can cause serotonin syndrome — a potentially fatal condition with hyperthermia, rigidity, autonomic instability, and mental status changes.
- MajorLinezolid and IV methylene blue — Both are MAO inhibitors. Do not combine with duloxetine unless the benefit outweighs the risk of serotonin syndrome. If urgent use is needed, discontinue duloxetine and monitor closely.
- MajorStrong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) — Fluvoxamine increases duloxetine AUC by approximately 6-fold. Ciprofloxacin increases it by approximately 5-fold. Concurrent use should be avoided due to significantly increased duloxetine levels and toxicity risk.
- MajorThioridazine — CONTRAINDICATED. Duloxetine inhibits CYP2D6, which metabolizes thioridazine. Elevated thioridazine levels can cause QT prolongation and serious ventricular arrhythmias.
- MajorOther serotonergic drugs (SSRIs, triptans, tramadol, St. John's wort) — Increased risk of serotonin syndrome when combined with other drugs that increase serotonin levels. Use with caution and monitor for symptoms: agitation, confusion, tachycardia, hyperthermia, muscle rigidity, tremor.
- ModerateNSAIDs, aspirin, and anticoagulants — SNRIs including duloxetine impair platelet serotonin uptake, increasing the risk of bleeding. Concurrent use with NSAIDs, aspirin, or anticoagulants further increases this risk. Use with caution.
- ModerateCYP2D6 substrates (metoprolol, desipramine, codeine) — Duloxetine is a strong CYP2D6 inhibitor. It can significantly increase blood levels of drugs metabolized by CYP2D6. For codeine (a prodrug activated by CYP2D6), duloxetine may reduce analgesic efficacy.
- ModerateAlcohol — Duloxetine can cause hepatotoxicity. Alcohol increases this risk. Duloxetine should not be prescribed to patients with substantial alcohol use. Combined hepatic effects can lead to severe liver injury.
Can I eat certain foods or drink alcohol with Duloxetine?
Duloxetine should NOT be used by people who consume substantial amounts of alcohol [1]. Both duloxetine and alcohol are metabolized by the liver, and their combination increases the risk of liver injury. The prescribing information specifically warns against use in patients with chronic liver disease or substantial alcohol use [1].
Duloxetine capsules should be swallowed whole with water [1]. They can be taken with or without food. Taking it with food may help reduce nausea, which is the most common initial side effect [1, 3].
Do NOT open the capsule and sprinkle the contents on food or mix with liquids [1]. The pellets inside the capsule have an enteric coating that protects them from stomach acid. If the coating is disrupted, the drug will be destroyed by gastric acid, significantly reducing absorption [1].
Caffeine is metabolized by CYP1A2, the same enzyme that metabolizes duloxetine [1, 12]. While this interaction is generally not clinically significant at normal caffeine intake, excessive caffeine may modestly affect duloxetine levels.
What is the typical dosage for Duloxetine?
Major depressive disorder (MDD) [1, 3]: - Starting dose: 30 mg once daily (some patients may start at 20 mg) - Target dose: 60 mg once daily (can be given as a single dose or 30 mg twice daily) - Maximum dose: 120 mg/day (limited evidence of additional benefit above 60 mg)
Generalized anxiety disorder (GAD) [1, 6]: - Starting dose: 30 mg once daily for 1 week, then increase to 60 mg once daily - Target dose: 60 mg once daily - Maximum dose: 120 mg/day
Diabetic peripheral neuropathic pain [1, 4]: - Dose: 60 mg once daily (no need for titration) - Maximum dose: 60 mg/day (higher doses did not show additional benefit in trials) [4]
Fibromyalgia [1, 5]: - Starting dose: 30 mg once daily for 1 week - Target dose: 60 mg once daily - Maximum dose: 60 mg/day
Chronic musculoskeletal pain [1, 14]: - Starting dose: 30 mg once daily for 1 week - Target dose: 60 mg once daily - Maximum dose: 60 mg/day
Available forms [1]: Delayed-release capsules: 20 mg, 30 mg, 40 mg, 60 mg
Renal impairment: Avoid in severe renal impairment (CrCl <30 mL/min) [1] Hepatic impairment: Do not use in patients with hepatic insufficiency [1]
Discontinuation [1, 8]: Taper gradually. A common taper: reduce to 30 mg daily for 2 weeks, then 20 mg daily for 2 weeks before stopping. Perahia et al. documented the importance of gradual discontinuation to minimize withdrawal symptoms [8].
How much does Duloxetine cost?
Generic duloxetine has been available since 2013 and is significantly more affordable than brand-name Cymbalta [9, 11].
Generic duloxetine 60 mg typically costs $5-$20 for a 30-day supply with a discount coupon (GoodRx, RxSaver) [11]. Brand-name Cymbalta can cost $400+ per month without insurance.
Most insurance plans (including Medicare Part D) cover generic duloxetine with modest copays, typically $5-$25 for a 30-day supply [11]. Prior authorization may be required for some plans.
Lilly (the manufacturer of Cymbalta) offers a patient assistance program for eligible uninsured patients [9].
Cost-saving tip: All duloxetine capsule strengths (20, 30, 40, 60 mg) typically cost the same at most pharmacies [11]. Do not ask for two 30 mg capsules instead of one 60 mg — use the single capsule formulation to minimize cost.
For patients paying cash, compare prices across pharmacies. Costco, independent pharmacies, and mail-order pharmacies often have the lowest prices [11].
Is Duloxetine safe during pregnancy or breastfeeding?
Pregnancy: Duloxetine is not assigned a specific pregnancy category under the current FDA labeling system [1]. Animal studies have shown adverse developmental effects. Third-trimester exposure to SNRIs has been associated with neonatal adaptation syndrome including respiratory distress, cyanosis, feeding difficulties, hypoglycemia, hypertonia/hypotonia, tremor, irritability, and seizures [1, 7]. These symptoms are generally self-limiting but may require extended hospitalization. Additionally, SNRI use late in pregnancy may increase the risk of persistent pulmonary hypertension of the newborn (PPHN) [1]. The decision to continue or discontinue duloxetine during pregnancy must weigh the risks of untreated maternal depression/anxiety against fetal risks [1, 7].
Breastfeeding: Duloxetine is excreted in breast milk [1]. The estimated relative infant dose is approximately 0.14-1.0% of the weight-adjusted maternal dose [15]. Limited published data have not reported adverse effects in breastfed infants. The decision to breastfeed while on duloxetine should consider the benefit of treatment, the benefit of breastfeeding, and the potential risk to the infant [1, 15].
Is there a generic version of Duloxetine?
Generic duloxetine has been available since December 2013 and is manufactured by multiple companies [9]. All generic versions are AB-rated by the FDA as therapeutically equivalent to Cymbalta.
There is no clinically meaningful difference between generic duloxetine and brand-name Cymbalta [1, 9]. The generic contains the same active ingredient, same enteric-coated delayed-release pellets, same strength, and must meet the same quality and bioequivalence standards.
Brand-name Cymbalta is rarely prescribed today [9]. Virtually all prescriptions are filled with generic duloxetine, which costs a small fraction of the original brand price.
Some patients report differences when switching between generic manufacturers [12]. If you experience changes in effectiveness or side effects after a manufacturer switch, discuss it with your pharmacist — they may be able to consistently stock one manufacturer.
For Caregivers
If you are a caregiver for someone starting or taking duloxetine, the FDA boxed warning requires close monitoring for suicidal thoughts and behavior, especially in patients under 25, during the first few months of treatment and after dose changes [1, 7].
Watch for warning signs: worsening depression, new or worsening anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, restlessness, unusual changes in behavior, or talk of suicide [7]. Report these to the prescriber immediately.
Ensure the person takes the medication consistently [1]. Missing doses can cause uncomfortable withdrawal-like symptoms [8]. If they want to stop, they must taper gradually under medical supervision [1, 8].
Be aware that duloxetine and alcohol are a dangerous combination [1]. If the person you care for has a history of heavy alcohol use, this medication may not be appropriate.
Monitor for signs of serotonin syndrome if duloxetine is combined with other serotonergic medications: confusion, rapid heart rate, fever, muscle rigidity, tremor, agitation [1, 12]. This requires emergency medical attention.
Frequently asked questions about Duloxetine
References
- [Regulatory] Cymbalta (duloxetine) delayed-release capsules prescribing information. Eli Lilly and Company. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s050lbl.pdf Accessed 2025-01-15.
- [Regulatory] Duloxetine hydrochloride. National Library of Medicine DailyMed drug label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b0e5de40-a89e-42b3-9ad3-0aa2c26dff90 Accessed 2025-01-15.
- [Regulatory] Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63(4):308-315. https://pubmed.ncbi.nlm.nih.gov/11565545/ Accessed 2025-01-15.
- [Regulatory] Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1-2):109-118. https://pubmed.ncbi.nlm.nih.gov/15044629/ Accessed 2025-01-15.
- [Regulatory] Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum. 2004;50(9):2974-2984. https://pubmed.ncbi.nlm.nih.gov/15673745/ Accessed 2025-01-15.
- [Regulatory] Rynn M, Russell J, Erickson J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety. 2008;25(3):182-189. https://pubmed.ncbi.nlm.nih.gov/17114070/ Accessed 2025-01-15.
- [Regulatory] FDA: Suicidality in Children and Adolescents Being Treated with Antidepressant Medications. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/suicidality-children-and-adolescents-being-treated-antidepressant-medications Accessed 2025-01-15.
- [Regulatory] Perahia DG, Kajdasz DK, Desaiah D, Haddad PM. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2005;89(1-3):207-212. https://pubmed.ncbi.nlm.nih.gov/19573458/ Accessed 2025-01-15.
- [Regulatory] Drugs@FDA: FDA-Approved Drugs — Cymbalta NDA 021427. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021427 Accessed 2025-01-15.
- [Regulatory] Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25(6):871-880. https://pubmed.ncbi.nlm.nih.gov/18311146/ Accessed 2025-01-15.
- [Observational] GoodRx. Duloxetine Prices, Coupons & Savings Tips. https://www.goodrx.com/duloxetine Accessed 2025-01-15.
- [Regulatory] UpToDate. Duloxetine: Drug information. Wolters Kluwer. https://www.uptodate.com/contents/duloxetine-drug-information Accessed 2025-01-15.
- [Regulatory] Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366. https://pubmed.ncbi.nlm.nih.gov/24005186/ Accessed 2025-01-15.
- [Regulatory] Skljarevski V, Zhang S, Desaiah D, et al. Duloxetine vs. placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010;11(12):1282-1290. https://pubmed.ncbi.nlm.nih.gov/22968964/ Accessed 2025-01-15.
- [Clinical] Dhaliwal JS, Spurling BC, Molla M. Duloxetine. StatPearls. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK549806/ Accessed 2025-01-15.
Written and fact-checked by PrescriptionDrugs.org Editorial Team
Last updated: